Copyright Reports & Markets. All rights reserved.

Global Viral Vector and Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Viral Vector and Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Adenovirus
    • 1.3.3 Fowlpox Virus
    • 1.3.4 Attenuated Yellow Fever
    • 1.3.5 Vaccinia Virus Vectors
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Viral Vector and Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Research Institutes
    • 1.4.3 Biopharmaceutical Companies
    • 1.4.4 Others
  • 1.5 Global Viral Vector and Vaccine Market Size & Forecast
    • 1.5.1 Global Viral Vector and Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Viral Vector and Vaccine Sales Quantity (2021-2032)
    • 1.5.3 Global Viral Vector and Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 ABL
    • 2.1.1 ABL Details
    • 2.1.2 ABL Major Business
    • 2.1.3 ABL Viral Vector and Vaccine Product and Services
    • 2.1.4 ABL Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 ABL Recent Developments/Updates
  • 2.2 Addgene
    • 2.2.1 Addgene Details
    • 2.2.2 Addgene Major Business
    • 2.2.3 Addgene Viral Vector and Vaccine Product and Services
    • 2.2.4 Addgene Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Addgene Recent Developments/Updates
  • 2.3 Aldevron
    • 2.3.1 Aldevron Details
    • 2.3.2 Aldevron Major Business
    • 2.3.3 Aldevron Viral Vector and Vaccine Product and Services
    • 2.3.4 Aldevron Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Aldevron Recent Developments/Updates
  • 2.4 Boehringer Ingelheim International GmbH
    • 2.4.1 Boehringer Ingelheim International GmbH Details
    • 2.4.2 Boehringer Ingelheim International GmbH Major Business
    • 2.4.3 Boehringer Ingelheim International GmbH Viral Vector and Vaccine Product and Services
    • 2.4.4 Boehringer Ingelheim International GmbH Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
  • 2.5 Brammer Bio
    • 2.5.1 Brammer Bio Details
    • 2.5.2 Brammer Bio Major Business
    • 2.5.3 Brammer Bio Viral Vector and Vaccine Product and Services
    • 2.5.4 Brammer Bio Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Brammer Bio Recent Developments/Updates
  • 2.6 Charles River Laboratories
    • 2.6.1 Charles River Laboratories Details
    • 2.6.2 Charles River Laboratories Major Business
    • 2.6.3 Charles River Laboratories Viral Vector and Vaccine Product and Services
    • 2.6.4 Charles River Laboratories Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Charles River Laboratories Recent Developments/Updates
  • 2.7 Creative-Biogene
    • 2.7.1 Creative-Biogene Details
    • 2.7.2 Creative-Biogene Major Business
    • 2.7.3 Creative-Biogene Viral Vector and Vaccine Product and Services
    • 2.7.4 Creative-Biogene Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Creative-Biogene Recent Developments/Updates
  • 2.8 Fujifilm Corporation
    • 2.8.1 Fujifilm Corporation Details
    • 2.8.2 Fujifilm Corporation Major Business
    • 2.8.3 Fujifilm Corporation Viral Vector and Vaccine Product and Services
    • 2.8.4 Fujifilm Corporation Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Fujifilm Corporation Recent Developments/Updates
  • 2.9 General Electric
    • 2.9.1 General Electric Details
    • 2.9.2 General Electric Major Business
    • 2.9.3 General Electric Viral Vector and Vaccine Product and Services
    • 2.9.4 General Electric Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 General Electric Recent Developments/Updates
  • 2.10 Waisman Biomanufacturing
    • 2.10.1 Waisman Biomanufacturing Details
    • 2.10.2 Waisman Biomanufacturing Major Business
    • 2.10.3 Waisman Biomanufacturing Viral Vector and Vaccine Product and Services
    • 2.10.4 Waisman Biomanufacturing Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Waisman Biomanufacturing Recent Developments/Updates
  • 2.11 Novasep
    • 2.11.1 Novasep Details
    • 2.11.2 Novasep Major Business
    • 2.11.3 Novasep Viral Vector and Vaccine Product and Services
    • 2.11.4 Novasep Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Novasep Recent Developments/Updates
  • 2.12 Pfizer
    • 2.12.1 Pfizer Details
    • 2.12.2 Pfizer Major Business
    • 2.12.3 Pfizer Viral Vector and Vaccine Product and Services
    • 2.12.4 Pfizer Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Pfizer Recent Developments/Updates
  • 2.13 Spark Therapeutics
    • 2.13.1 Spark Therapeutics Details
    • 2.13.2 Spark Therapeutics Major Business
    • 2.13.3 Spark Therapeutics Viral Vector and Vaccine Product and Services
    • 2.13.4 Spark Therapeutics Viral Vector and Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Spark Therapeutics Recent Developments/Updates

3 Competitive Environment: Viral Vector and Vaccine by Manufacturer

  • 3.1 Global Viral Vector and Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Viral Vector and Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global Viral Vector and Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Viral Vector and Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Viral Vector and Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Viral Vector and Vaccine Manufacturer Market Share in 2025
  • 3.5 Viral Vector and Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Viral Vector and Vaccine Market: Region Footprint
    • 3.5.2 Viral Vector and Vaccine Market: Company Product Type Footprint
    • 3.5.3 Viral Vector and Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Viral Vector and Vaccine Market Size by Region
    • 4.1.1 Global Viral Vector and Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Viral Vector and Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global Viral Vector and Vaccine Average Price by Region (2021-2032)
  • 4.2 North America Viral Vector and Vaccine Consumption Value (2021-2032)
  • 4.3 Europe Viral Vector and Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Viral Vector and Vaccine Consumption Value (2021-2032)
  • 4.5 South America Viral Vector and Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Viral Vector and Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Viral Vector and Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global Viral Vector and Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global Viral Vector and Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Viral Vector and Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global Viral Vector and Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global Viral Vector and Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Viral Vector and Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America Viral Vector and Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America Viral Vector and Vaccine Market Size by Country
    • 7.3.1 North America Viral Vector and Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Viral Vector and Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Viral Vector and Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe Viral Vector and Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe Viral Vector and Vaccine Market Size by Country
    • 8.3.1 Europe Viral Vector and Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Viral Vector and Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Viral Vector and Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Viral Vector and Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Viral Vector and Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Viral Vector and Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Viral Vector and Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Viral Vector and Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America Viral Vector and Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America Viral Vector and Vaccine Market Size by Country
    • 10.3.1 South America Viral Vector and Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Viral Vector and Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Viral Vector and Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Viral Vector and Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Viral Vector and Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Viral Vector and Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Viral Vector and Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Viral Vector and Vaccine Market Drivers
  • 12.2 Viral Vector and Vaccine Market Restraints
  • 12.3 Viral Vector and Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Viral Vector and Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Viral Vector and Vaccine
  • 13.3 Viral Vector and Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Viral Vector and Vaccine Typical Distributors
  • 14.3 Viral Vector and Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Viral Vector and Vaccine market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Viral Vector and Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Viral Vector and Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Viral Vector and Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Viral Vector and Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Viral Vector and Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Viral Vector and Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Viral Vector and Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ABL, Addgene, Aldevron, Boehringer Ingelheim International GmbH, Brammer Bio, Charles River Laboratories, Creative-Biogene, Fujifilm Corporation, General Electric, Waisman Biomanufacturing, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Viral Vector and Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Adenovirus
    Fowlpox Virus
    Attenuated Yellow Fever
    Vaccinia Virus Vectors
    Market segment by Application
    Research Institutes
    Biopharmaceutical Companies
    Others
    Major players covered
    ABL
    Addgene
    Aldevron
    Boehringer Ingelheim International GmbH
    Brammer Bio
    Charles River Laboratories
    Creative-Biogene
    Fujifilm Corporation
    General Electric
    Waisman Biomanufacturing
    Novasep
    Pfizer
    Spark Therapeutics
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Viral Vector and Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Viral Vector and Vaccine, with price, sales quantity, revenue, and global market share of Viral Vector and Vaccine from 2021 to 2026.
    Chapter 3, the Viral Vector and Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Viral Vector and Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Viral Vector and Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Viral Vector and Vaccine.
    Chapter 14 and 15, to describe Viral Vector and Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now